naptumomab estafenatox
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma. — Wikipedia
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Apr 1, 2003 (NCT00056537)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2/Phase 3
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Melanoma · Phase 1
- Mesothelioma · Phase 1
- Mutation · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Trophoblast glycoproteinINHIBITOR
TPBG inhibitor
TPBG other
The therapeutic effect is associated with activation of SAg-binding T cells. The SAg-binding T lymphocytes expand, differentiate to effector cells, and infiltrate the tumor. The therapeutic efficacy is most likely related to the dual mechanism of tumor cell killing: (1) direct lysis by cytotoxic T lymphocytes of tumor cells expressing the antigen recognized by the antibody moiety of the fusion protein and (2) secretion of cytokines eliminating antigen-negative tumor cell variants.
- Unspecified targetOTHER
Immunostimulant
Antibody linked to tumor-targeted superantigen; SEA-E-120.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- estafenatox
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNaptumomab estafenatox ↗
- ChEMBLCHEMBL2108248 ↗
- ChEMBLCHEMBL1743045 ↗
Also known as
- abr-217620
- abr-217620
- anyara
- anyara tts cd3
- naptumomab estafenatox
- naptumomab estafenatox
- naptumomab estafenatox
- naptumomab estafenatox
- tts-cd3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04880863 | Phase 2 | Jul 29, 2021 | NeoTX Therapeutics Ltd., Translational Drug Development |
| NCT03983954 | Phase 1 | Aug 1, 2019 | AstraZeneca, NeoTX Therapeutics Ltd. |
| NCT00420888 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2007 | Active Biotech AB |
| NCT00132379 | Phase 1 | Nov 1, 2005 | Active Biotech AB |
| NCT00056537 | Phase 1 | Apr 1, 2003 | Active Biotech AB |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Active Biotech AB | For profit | 3 | 3 | 2 | 2003 |
| NeoTX Therapeutics Ltd. | For profit | 2 | 2 | 2 | 2019 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2019 |
| Translational Drug Development | For profit | 1 | 0 | 1 | 2021 |